恰加斯心肌病的进展发生率与预测因素:克氏锥虫血清阳性者的长期随访
该研究在巴西两个中心纳入克氏锥虫血清阳性献血者、血清阴性对照及已确诊恰加斯心肌病患者,于2008-2010年及2018-2019年随访。血清阳性者心肌病发生率为13.8/1000人年,高于血清阴性者的4.6/1000人年,绝对发生率差为9.2/1000人年;基线抗体水平与心肌病发生相关(调整OR 1.4)。
要点
- 克氏锥虫血清阳性献血者心肌病发生率为13.8/1000人年,显著高于血清阴性者。
- 基线克氏锥虫抗体水平与心肌病发生独立相关(调整OR 1.4)。
- 基线无心肌病的血清阳性者死亡率与血清阴性者无差异。
核心结论
- 克氏锥虫血清阳性者心肌病发生风险显著高于血清阴性者,基线抗体水平是疾病活动性和进展风险的标志。
研究设计与样本
- 在巴西两个中心血库选择克氏锥虫血清阳性献血者,以年龄、性别和献血时间匹配血清阴性对照,并从三级门诊招募已确诊恰加斯心肌病患者。
- 纳入499例血清阳性献血者(年龄48±10岁,52%男性)、488例血清阴性献血者(年龄49±10岁,49%男性)和101例已确诊恰加斯心肌病患者(年龄48±8岁,59%男性)。
- 于2008-2010年基线和2018-2019年随访时进行医学检查、采血、心电图和超声心动图。
主要发现
- 已确诊心肌病患者死亡率为80.9例/1000人年(54/101,53%);基线有心肌病的血清阳性献血者为15.1例/1000人年(17/114,15%)。
- 基线无心肌病的血清阳性献血者死亡率为3.7例/1000人年(15/385,4%),与血清阴性献血者的3.6例/1000人年(17/488,3%)无差异。
- 血清阳性献血者心肌病发生率为13.8(95%CI 9.5-19.6)例/1000人年(32/262,12%),血清阴性对照为4.6(95%CI 2.3-8.3)例/1000人年(11/277,4%)。
- 克氏锥虫血清阳性相关的绝对发生率差为9.2(95%CI 3.6-15.0)例/1000人年。
- 基线克氏锥虫抗体水平与心肌病发生相关(调整OR 1.4 [95%CI 1.1-1.8])。
关键数值与推荐
- 心肌病定义为左心室射血分数<50%或QRS波时限≥120 ms,或两者兼有。
- 采用逆概率加权进行选择偏倚的敏感性分析,以处理失访。
临床怎么用
- 对克氏锥虫血清阳性者应监测基线抗体水平,其与心肌病进展风险相关。
- 血清阳性者需长期随访心电图和超声心动图以早期发现心肌病。
- 基线无心肌病的血清阳性者短期死亡率与血清阴性者相近,但心肌病发生风险仍较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are few contemporary cohorts of Trypanosoma cruzi-seropositive individuals, and the basic clinical epidemiology of Chagas disease is poorly understood. Herein, we report the incidence of cardiomyopathy and death associated with T. cruzi seropositivity. METHODS: Participants were selected in blood banks at 2 Brazilian centers. Cases were defined as T. cruzi-seropositive blood donors. T. cruzi-seronegative controls were matched for age, sex, and period of donation. Patients with established Chagas cardiomyopathy were recruited from a tertiary outpatient service. Participants underwent medical examination, blood collection, ECG, and echocardiogram at enrollment (2008-2010) and at follow-up (2018-2019). The primary outcomes were all-cause mortality and development of cardiomyopathy, defined as the presence of a left ventricular ejection fraction <50% or QRS complex duration ≥120 ms, or both. To handle loss to follow-up, a sensitivity analysis was performed using inverse probability weights for selection. RESULTS: We enrolled 499 T. cruzi-seropositive donors (age 48±10 years, 52% male), 488 T. cruzi-seronegative donors (age 49±10 years, 49% male), and 101 patients with established Chagas cardiomyopathy (age 48±8 years, 59% male). The mortality in patients with established cardiomyopathy was 80.9 deaths/1000 person-years (py) (54/101, 53%) and 15.1 deaths/1000 py (17/114, 15%) in T. cruzi-seropositive donors with cardiomyopathy at baseline. Among T. cruzi-seropositive donors without cardiomyopathy at baseline, mortality was 3.7 events/1000 py (15/385, 4%), which was no different from T. cruzi-seronegative donors with 3.6 deaths/1000 py (17/488, 3%). The incidence of cardiomyopathy in T. cruzi-seropositive donors was 13.8 (95% CI, 9.5-19.6) events/1000 py (32/262, 12%) compared with 4.6 (95% CI, 2.3-8.3) events/1000 py (11/277, 4%) in seronegative controls, with an absolute incidence difference associated with T. cruzi seropositivity of 9.2 (95% CI, 3.6-15.0) events/1000 py. T. cruzi antibody level at baseline was associated with development of cardiomyopathy (adjusted odds ratio, 1.4 [95% CI, 1.1-1.8]). CONCLUSIONS: We present a comprehensive description of the natural history of T. cruzi seropositivity in a contemporary patient population. The results highlight the central importance of anti-T. cruzi antibody titer as a marker of Chagas disease activity and risk of progression.
引用
- Nunes MCP, Buss LF, Silva JLP, et al. Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of Trypanosoma cruzi-Seropositive Individuals. Circulation. 2021. PMID: 34565171. doi:10.1161/CIRCULATIONAHA.121.055112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。